Bibliography
- Rosini M, Bolognesi M, Giardina D, et al. Recent advances in α-adrenoceptor antagonists as pharmacological tools and therapeutic agents. Curr Top Med Chem 2007;7(2):147
- Michelotti GA, Schwinn DA. Mechanistic insights into the role of α-adrenergic receptors in lower urinary tract symptoms. Curr Urol Rep 2004;5(4):258
- Cutis N. The use of α-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia. J Urol 2003;62:34
- Lowe FC. Role of the newer α-adrenergic receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 2004;26(11):1701
- Muramatsu I, Suzuki F, Tanaka T, et al. α-Adrenoceptor subtypes and α-adrenoceptor antagonists. J Pharm Soc Jap 2006;126:187
- Bruno JF, Whittaker J, Song J, et al. Molecular cloning and sequencing of a cDNA encoding a human α-adrenergic receptor. Biochem Biophys Res Commun 1991;179:1485
- Ramarao CS, Kincade Denker JM, Perez DM, et al. Genomic organization and expression of the human α-adrenergic receptor. J Biol Chem 1992;267:21936
- Hirasawa A, Horie K, Tanaka T, et al. Cloning, functional expression and tissue distribution of human cDNA for the α-adrenergic receptor. Biochem Biophys Res Commun 1993;195:902
- Forray C, Bard JA, Wetzel J, et al. The α-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human α subtype. Mol Pharmacol 1994;45:703
- Synaptic Corparation. Use of α specific compounds to treat benign prostatic hyperplasia. US5403847; 1995
- Synaptic Corparation. Aromatic amine derivatives. US5508306; 1996
- Synaptic Corparation. Dihydropyridines and new uses thereof. US5767131; 1998
- Synaptic Corparation. 5-(Heterocyclic alkyl)-6-aryl-dihydropyrimidines. US5942517; 1999
- Yoshisa M, Homma Y, Kawabe K. Silodosin, a novel selective α-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2007;16(12):1955-65
- Chiu C, Gluchowski C, Forray C. Design and synthesis of an α-adrenergic receptor subtype selective antagonist from BE2254. Chem Biol Drug Design 2006;68(1):76
- Wetzel JM, Miao SW, Forray C, et al. Discovery of α-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J Med Chem 1995;38:1579
- Wong WC, Chiu G, Wetzel JM, et al. Identification of a dihydropyridine as a potent α-adrenoceptor selective antagonist that inhibits phenylephrin-induced contractile of the human prostate. J Med Chem 1998;41:2643
- Lagu B, Tian D, Chiu G, et al. Synthesis and evaluation of furo[3,4-d]pyrimidinones as selective α-adrenergic receptor antagonists. Bioorg Med Chem Lett 2000;10:175
- Kawabe K, Yoshida M, Homma Y. Silodosin, a new α-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia: results of a Phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98(5):1019
- Blue DR Jr, Grino PB, Jung DT, et al. Evaluation of Ro70-0004, a selective α-adrenoceptor antagonist, in men with benign prostatic hyperplasia (BPH). [abstract] In: Proceedings of the Fifth International Consultation on BPH 2000 June 25
- Ilampel C, Dolber PC, Smith MP, et al. Modulation of bladder α-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 2002;167:1513
- Gu B, Reiter JP, Schwinn DA, et al. Effects of α-adrenergic receptor subtype selective antagonists on lower Urinary tract function in rats with bladder outlet obstruction. J Urol 2004;172:758
- Smith MS, Scharnbra UM, Wilson KH, et al. α-Adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding α-adrenergic receptor subtypes at four distinct levels. Brain Res Mol Brain Res 1999;63:254
- Andersson K-E, Gratzke C. Pharmacology of α-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 2007;4(7):368
- Cavalli A, Lattion AL, Hummler E, et al. Decreased blood pressure response in mice deficient of the α-adrenergic receptor. Proc Natl Acad Sci USA 1997;94:11589
- Schwinn DA, Price DT, Narayan P. α-adrenoceptor subtype selectivity and lower urinary track symptoms. Mayo Clinic Proc 2004;79(11):1423
- Roehrborn CG, Schwinn D. α-adrenergic receptors and their inhibitors in lower urinary track symptoms and benign prostatic hyperplasia. J Urol 2004;171:1029
- Sarma PKS, Tiwari A, Pal A. α-adrenoceptors as potential therapeutic targets. Expert Opin Ther Patents 2005;15(10): 1333
- Daniels DV, Gever JR, Jasper JR, et al. Human cloned alpha-1A adrenoceptor isoforms display alpha 1L-adrenoceptor pharmacology in functional studies. Eur J Pharmacol 1999;370:337
- Lowe FC. Role of the newer alpha-adrenergic receptor antagonists in the treatment of benign prostatic hyperplasis related lower urinary track symptoms. Clin Ther 2004;26:1701
- Li S, Chiu G, Connolly PJ, et al. 1-Arylpiperazinyl-4-cyclohexylamine derived isoindole-1,3-diones as potent and selective α adrenergic receptor ligands. Bioorg Med Chem Lett 2007;17(6):1646
- Chiu G, Li S, Connolly PJ, et al. (Phenylpiperazinyl)cyclohexylureas: Discovery of α-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). Bioorg Med Chem Lett 2008;18(2):640
- Chiu G, Li S, Connolly PJ, et al. (Arylpiperazinyl)cyclohexylsufonamides: discovery of α-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). Bioorg Med Chem Lett 2007;17(12):3292
- Chiu G, Li S, Connolly PJ, et al. (Phenylpiperidinyl)cyclohexylsulfonamides: Development of α -selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). Bioorg Med Chem Lett 2007;17(14):3930
- Chiu G, Li S, Cai H, et al. Aminocyclohexylsulfonamides: Discovery of metabolically stable of α -selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). Bioorg Med Chem Lett 2007;17(22):6123
- Ranbaxy Laboratories. Isoindoledione derivatives as adrenergic receptor antagonists. WO07029156; 2007
- Ranbaxy Laboratories. Acid addition salts of isoindoles acting as adrenergic receptor antagonists. WO07010504; 2007
- Ranbaxy Laboratories. Arylpiperazines useful as adrenergic receptor antagonists. WO06051374; 2007
- Ranbaxy Laboratories. Piperazine derivatives useful as adrenergic receptor antagonists. WO06051399; 2006
- Ranbaxy Laboratories. Succinimide and glutarimide derivatives as adrenergic receptor antagonists. WO07029078; 2007
- Ranbaxy Laboratories. Adrenergic receptor antagonists. WO06117760; 2006
- Ranbaxy Laboratories. Piperazine derivatives as adrenergic receptor antagonists. WO06018815; 2006
- Ranbaxy Laboratories. Thiazolidinedione derivatives as alpha adrenergic receptor antagonists. WO06013445; 2006
- Janssen Pharmaceutica, NV. Dihydroindolyl Methanones as alpha 1A/1D adrenoceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. WO06088954; 2006
- Reitz AB, Baxter EW, Codd EE, et al. Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic α-1 receptors. J Med Chem 1998;41(12):1997
- Reitz AB, Mcdonnell ME, Baxter EW, et al. The synthesis and evaluation of the major metabolites of mazapertine. Bioorg Med Chem Lett 1997;7(14):1927
- Reitz AB, Bennett DJ, Blum PS, et al. A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/α 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem 1998;37(8):1060
- Janssen Pharmaceutica, NV. Substituted isoindole-1,3-diones. WO07001818; 2007
- Janssen Pharmaceutica, NV. Substituted {4(4-phenyl-piperazin-1yl)-cyclohexyl}-urea compounds. WO07005214; 2007
- Janssen Pharmaceutica, NV. Piperidinyl substituted cyclohexane-1,4-diamines. WO06101859; 2006
- Janssen Pharmaceutica, NV. Piperazinyl substituted cyclohexane-1,4-diamines. WO06104686; 2006
- Janssen Pharmaceutica, NV. Cyclohexyldiamines as selective alpha 1A/1D adrenoceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. WO06050048; 2006